Image

    Safety and Efficacy of Orally Administered Cepharanthine in Non-Hospitalized, Asymptomatic or Mild COVID-19 Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

    Jianyi Wei, Shuming Pan, Shupeng Liu … Hai Li

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medrxiv.org →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2 Cell Research · 2021
    2. Roles of Existing Drugs and Drug Targets for COVID-19 Management Metabolism Open · 2021
    3. Structural Insights Into SARS-CoV-2 Spike Protein and Its Natural Mutants Found in Mexican Population Scientific Reports · 2021
    4. Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19 Pharmacological Reports · 2020
    5. Cepharanthine: An Update of Its Mode of Action, Pharmacological Properties, and Medical Applications Phytomedicine · 2019